Form 8-K - Current report:
SEC Accession No. 0001558370-22-017843
Filing Date
2022-11-14
Accepted
2022-11-14 17:02:31
Documents
15
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20221114x8k.htm   iXBRL 8-K 37752
2 EX-99.1 fbio-20221114xex99d1.htm EX-99.1 552904
3 GRAPHIC fbio-20221114xex99d1001.jpg GRAPHIC 12080
  Complete submission text file 0001558370-22-017843.txt   798315

Data Files

Seq Description Document Type Size
4 EX-101.SCH fbio-20221114.xsd EX-101.SCH 4442
5 EX-101.DEF fbio-20221114_def.xml EX-101.DEF 14631
6 EX-101.LAB fbio-20221114_lab.xml EX-101.LAB 16578
7 EX-101.PRE fbio-20221114_pre.xml EX-101.PRE 14303
9 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20221114x8k_htm.xml XML 7282
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 221387272
SIC: 2834 Pharmaceutical Preparations